Cargando…
Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?
In France, more than 2.5 million patients are currently treated with levothyroxine, mainly as the marketed product Levothyrox(®). In March 2017, at the request of French authorities, a new formulation of Levothyrox(®) was licensed, with the objective of avoiding stability deficiencies of the old for...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584220/ https://www.ncbi.nlm.nih.gov/pubmed/30949873 http://dx.doi.org/10.1007/s40262-019-00747-3 |